News

Fintel reports that on July 16, 2025, B of A Securities downgraded their outlook for Centene (NYSE:CNC) from Neutral to ...
Centene Corporation (NYSE:CNC) is one of the Best Beaten Down Stocks to Buy Now. Bank of America downgraded the company’s stock to “Underperform” from “Neutral,” reducing the price objective to $30 ...
The Clayton-based health giant is likely to face increased challenges as federal government tightens Medicaid eligibility and ...
Shares of Centene are experiencing a historic collapse this week. Wednesday marked the worst single-day performance in the company's history.
Investing.com -- Shares of Centene (NYSE:CNC) plunged more than 32% in premarket trading Wednesday after the company pulled its 2025 guidance, citing unexpectedly poor risk adjustment results in ...
Centene aims to be a top provider of government-sponsored health plans. Although it has grown at a solid clip organically, it also has made significant acquisitions—most notably WellCare in ...
Centene's Fair Value Cut, Uncertainty Rating Downgraded on Individual Plan and Medicaid Headwinds Julie Utterback Jul 2, 2025 Share ...
Centene (NYSE:CNC) stock was downgraded by Argus citing an uncertain outlook for its certain state-level operations and its Medicare Advantage business. Read more here.
Meanwhile, Barclays downgraded Centene from Overweight to Equalweight, expressing concerns about the Part D and ACA segments and adjusting their earnings per share estimates downward for 2025 and ...
Centene's stock was suffering a record 39.2% selloff in recent trading, as a miscalculation of rising healthcare costs led the company to withdraw its full-year earnings outlook.
Jefferies downgraded Centene (CNC) to Underperform from Hold with a price target of $52, down from $68. After analysis of Affordable Care Act Exchange data, the firm sees potential for ...
On June 2, an analyst from Barclays downgraded Centene Corporation’s (NYSE:CNC) rating from Overweight to Equal-Weight and lowered its price target from $84 to $65. The downgrade follows Centene ...